

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)



(10) International Publication Number
WO 2024/031101 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2023/071794

(22) International Filing Date:
07 August 2023 (07.08.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/395,445 05 August 2022 (05.08.2022) US

(71) Applicant: **SANEGENE BIO USA INC.** [US/US]; 300 TradeCenter, Suite 5500, Woburn, Massachusetts 01801 (US).

(72) Inventors: **ZHANG, Chunyang**; 300 TradeCenter, Suite 5500, Woburn, Massachusetts 01801 (US). **YANG, Zhongfa**; 300 TradeCenter, Suite 5500, Woburn, Massachusetts 01801 (US). **WANG, Shiyu**; 300 TradeCenter, Suite 5500, Woburn, Massachusetts 01801 (US). **WANG, Weimin**; 300 TradeCenter, Suite 5500, Woburn, Massachusetts 01801 (US).

(74) Agent: **CHEN, Chen et al.**; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: DOUBLE STRANDED RNA TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF

FIG. 1

in vitro Compound Potency at 0.02 nM



(57) Abstract: The disclosure relates to isolated oligonucleotides comprising duplex regions targeting angiotensin-like 3 (AGT), and delivery systems, kits and compositions comprising same, and methods of using same for inhibiting or downregulating AGT.

[Continued on next page]

WO 2024/031101 A1

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*